1.	A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma Phase: Phase IV Type: Natural history/Epidemiology, Treatment Status: Closed Age: Age not specified Sponsor: Pharmaceutical / Industry Protocol IDs: AVF2941n, NCT00097578
2.	A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML18491, NCT00118755
3.	A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML18527, NCT00121836
4.	A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO19390, NCT00451906
5.	Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without Bevacizumab in Patients With Advanced, Metastatic, or Recurrent Non-Squamous Cell Non-Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-4599, CALGB-E4599, E4599, NCT00021060
6.	The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: AG0501CR, NCT00294359
7.	First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D8480C00013, Eudract Number 2005-003440-66, NCT00384176
8.	Phase III Randomized Study of Bevacizumab (rhuMAb VEGF) With Fluorouracil and Leucovorin Calcium With or Without Irinotecan in Patients With Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GENENTECH-AVF2107g, UCLA-0008022, NCT00012233
9.	Phase III Randomized Study of Bevacizumab With Capecitabine Versus Capecitabine Alone in Women With Previously Treated Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: GENENTECH-AVF2119g, GUMC-00299, MSKCC-01008, UAB-0028, UAB-F001009003, NCT00012285
10.	Phase III Randomized Study of Oxaliplatin, Fluorouracil, and Leucovorin Calcium With or Without Bevacizumab Versus Bevacizumab Only in Patients With Previously Treated Advanced or Metastatic Colorectal Adenocarcinoma Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: E-3200, NCT00025337, E3200
11.	Phase III Randomized Study of Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-2100, NCCTG-E2100, CAN-NCIC-MAC3, NSABP-E2100, E2100, NCT00028990, MAC3
12.	Phase III Randomized Study of Oxaliplatin and Bevacizumab (Avastin™) With Fluorouracil and Leucovorin Calcium or Capecitabine in Patients With Advanced Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PROLOGUE-SANOFI-ARD5099, SANOFI-ARD5099, NCT00062426
13.	Phase III Randomized Study of Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab Versus Capecitabine, Oxaliplatin, and Bevacizumab in Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0303, S0303, ECOG-S0303, NCT00070122
14.	Phase III Randomized Study of Interferon alfa-2b With or Without Bevacizumab in Patients With Advanced Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-90206, CAN-NCIC-REC1, ECOG-CALGB-90206, NCT00072046, REC1
15.	A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NO16966, NCT00069095
16.	Phase III Randomized Study of Gemcitabine With Versus Without Bevacizumab in Patients With Locally Advanced or Metastatic Adenocarcinoma of the Pancreas Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-80303, ECOG-80303, NCT00088894
17.	Phase III Randomized Study of Adjuvant Chemotherapy Comprising Fluorouracil, Leucovorin Calcium, and Oxaliplatin With Versus Without Bevacizumab in Patients With Resected Stage II or III Adenocarcinoma of the Colon Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NSABP-C-08, NCT00096278
18.	Phase III Randomized Study of Docetaxel and Prednisone With Versus Without Bevacizumab in Patients With Hormone-Refractory Metastatic Adenocarcinoma of the Prostate Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-90401, ECOG-90401, NCT00110214
19.	Phase III Randomized Study of Adjuvant Oxaliplatin, Leucovorin Calcium, and Fluorouracil (FOLFOX-4) Versus Bevacizumab and FOLFOX-4 Versus Bevacizumab, Oxaliplatin, and Capecitabine in Patients With High-Risk Stage II or Stage III Colon Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0412086-01, ROCHE-BO17920A, NCT00112918
20.	PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20040249, NCT00115765
21.	Phase III Randomized Study of Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Bevacizumab in Patients With Resected Stage II Colon Cancer and at High Risk for Recurrence Based on Molecular Markers Phase: Phase III Type: Treatment Status: Temporarily closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E5202, E5202, NCT00217737
22.	A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: OSI3364g, NCT00130728
23.	Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CAIRO2, NCT00208546
24.	Trial of Cetuximab, Bevacizumab and 5FU/Leucovorin Versus Oxaliplatin, Bevacizumab and 5FU/Leucovorin in Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CA225251, NCT00252564
25.	A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AVF3671g, NCT00257608